ArticleThe Kaohsiung journal of medical sciences2025
IGF2BP2-induced circRNF20 facilitates breast cancer cell proliferation via the HuR/CDCA4 axis.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IGF2BP2-induced circRNF20 facilitates breast cancer cell proliferation via the HuR/CDCA4 axis.The Kaohsiung journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to explore the mechanism of insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) affecting the proliferation of breast cancer (BC) cells. The expression of IGF2BP2, circRNA ring finger protein 20 (circRNF20), and cell division cycle-associated protein 4 (CDCA4) in human BC cells and normal breast epithelial cells was detected via RT-qPCR or Western blotting. After IGF2BP2 expression was altered, CCK-8 assay, colony formation assay, and EdU staining were performed to evaluate changes in the proliferation of BC cells. RNA immunoprecipitation (RIP) assay was used to analyze the binding of circRNF20 to IGF2BP2 or HuR, as well as the binding of HuR to CDCA4. RNA pull-down confirmed the interaction between circRNF20 and HuR. The stability of circRNF20 was tested after treatment with actinomycin D. A nude mouse xenograft tumor model was established to validate the effect of IGF2BP2 in vivo. IGF2BP2, circRNF20, and CDCA4 were highly expressed in BC cells. Silencing IGF2BP2 decreased the proliferation ability of BC cells. Mechanistically, the binding of IGF2BP2 to circRNF20 prevented circRNF20 degradation, thereby promoting the binding of circRNF20 to HuR and increasing the expression of CDCA4. The overexpression of circRNF20 or CDCA4 abolished the inhibitory effect of IGF2BP2 silencing on BC cell proliferation. In conclusion, the binding of IGF2BP2 to circRNF20 prevents its degradation, thus facilitating BC cell proliferation via the HuR/CDCA4 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.